Lilly Tops Biopharma Innovation Survey For First Time
New Entrants Include Seagen And Inctye
Executive Summary
Conducting sector survey for a tenth year, Idea Pharma’s Mike Rea said: “COVID-19 showed companies with more agile decision-making were more likely to succeed.”
You may also be interested in...
Pandemic Perspectives: COVID-19 Upended Drug Launches In Ways That Will Stick
Preliminary data from IQVIA suggest 2020 was one of the weakest in recent years for new launch trajectories although drug companies tell Scrip there are some lessons learned from promoting during the pandemic.
As Seagen Matures, CEO Siegall Talks About Moving The Growth Goalposts
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.